Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Acadia Healthcare Company Inc (ACHC) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance

Acadia Healthcare Company IncTrade
Citius Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Acadia Healthcare Company Inc vs Citius Pharmaceuticals Inc — how do they compare? Acadia Healthcare Company Inc trades at $31.28 (market cap $2.90B), while Citius Pharmaceuticals Inc trades at $0.71 (market cap $20.01M). The key difference: Acadia Healthcare Company Inc is far larger — about 144.9× Citius Pharmaceuticals Inc's market cap, and Acadia Healthcare Company Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

ACHCCTXR
Market Cap
$2.90B$20.01M
Sector
HealthHealth
52-Week High
$35.61$1.82
52-Week Low
$11.68$0.48
Enterprise Value
$5.29B$16.23M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Acadia Healthcare Company Inc

ACHC trades at $31.14, down 2.01% today, with a neutral technical signal and mixed fundamentals. The company reported Q2 2026 EPS of $0.38, beating estimates, but maintains a net loss of -$1.10B for 2025. Analyst consensus is bullish with a $36.00 price target, though ongoing legal investigations and negative profit margins present headwinds. Cash flow from operations improved to $211M in 2026, supporting operational stability amid challenges.

The outlook for ACHC hinges on execution of its turnaround strategy and resolution of legal issues. Upside potential exists if EBITDA guidance improvements and admissions growth persist, but risks from litigation and sustained losses warrant caution. The stock's current valuation at a P/E of 19.82 and P/S of 0.84 may attract value investors if profitability recovers.

Citius Pharmaceuticals Inc

CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.

The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Acadia Healthcare Company Inc

Acadia Healthcare is a leading provider of behavioral healthcare services across the US and Puerto Rico. It operates a network of psychiatric hospitals, residential treatment centers, and clinics for mental health and addiction recovery.

Read more on ACHC

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR